

PWE-023

**AZATHIOPRINE AND 6-THIOGUANINE BUT NOT  
6-MERCAPTOPYRIMIDINE INHIBIT INTRA-MACROPHAGE  
REPLICATION OF CROHN'S DISEASE ESCHERICHIA COLI**

doi:10.1136/gut.2011.239301.286

P Knight,<sup>1,2,\*</sup> B J Campbell,<sup>1</sup> J M Rhodes<sup>1</sup> <sup>1</sup>Gastroenterology, University of Liverpool, Liverpool, UK, <sup>2</sup>NIHR Biomedical Research Centre, Royal Liverpool University Hospital, Liverpool, UK

**Introduction** Crohn's disease is associated with increased mucosal colonisation by *E. coli* that have an adherent, invasive phenotype that includes intracellular survival and replication within macrophages. Drugs that prevent this replication might have a therapeutic effect. We previously reported that azathioprine enhances bacterial killing by macrophages<sup>1</sup> and therefore we evaluated the effect of its metabolites, namely 6-mercaptopurine and 6-thioguanine, at clinically relevant concentrations, on replication of *E. coli* within macrophages.

**Methods** Azathioprine metabolites, 6-mercaptopurine ( $4.2 \times 10^{-2}$  to  $4.2 \mu\text{M}$ ) and 6-thioguanine ( $8.2 \times 10^{-5}$  to  $820 \text{ fmol}/8 \times 10^8$  cells) were assessed for their effect on survival and replication of Crohn's *E. coli* isolate HM605 in J774-A1 macrophages in comparison to azathioprine ( $4.2 \times 10^{-12}$  to  $4.2 \mu\text{M}$ ). Macrophages were pre-treated with drugs for 24 h before bacterial infection. Cells were then infected with HM605 for 2 h to allow for internalisation. Extracellular bacteria were removed and killed with gentamicin ( $20 \mu\text{g}/\text{mL}$ ) for 1 h. Macrophages were then either lysed (at 3 h) or parallel cultures incubated for a further 3 h in the presence of gentamicin (6 h). Internalised bacteria were enumerated by overnight growth on LB agar.

**Results** As previously seen, Crohn's *E. coli* HM605 significantly replicated within macrophages at 6 h compared to 3 h post-infection levels and azathioprine, at doses of  $4.2 \times 10^{-9}$  to  $4.2 \mu\text{M}$ , resulted in suppression of *E. coli* intramacrophage replication (all  $p < 0.01$ ,  $N=3-8$ ) with a peak effect at  $4.2 \mu\text{M}$  (0.33 fold replication relative to controls;  $p < 0.001$ ,  $N=5$  Kruskal Wallis ANOVA). 6-thioguanine also suppressed *E. coli* replication in a dose dependent fashion with peak suppression at  $82 \text{ fmol}/8 \times 10^8$  cells (0.47 fold replication relative to control;  $p < 0.001$ ,  $N=4$ ). However, 6-mercaptopurine did not suppress *E. coli* replication at any concentration tested.

**Conclusion** The enhancement of macrophage killing of intracellular *E. coli* by azathioprine and 6-thioguanine but not 6-mercaptopurine is intriguing. It might reflect the known ability of azathioprine but not 6-mercaptopurine to inhibit inducible nitric oxide synthase<sup>2</sup>. The effect of 6-thioguanine on nitric oxide synthase has yet to be assessed. These effects of azathioprine and 6-thioguanine on bacterial killing by macrophages may be relevant to some of their therapeutic effects, perhaps particularly in fistulating Crohn's disease.

**Competing interests** P. Knight: None Declared, B. Campbell: None Declared, J. Rhodes Consultant for: Proctor & Gamble and Falk, Speaker bureau with: Abbott, Falk, Ferring, Proctor & Gamble and Schering Plough

**Keywords** 6-mercaptopurine, azathioprine, Crohn's disease, escherichia coli, macrophages, thioguanine.

## REFERENCES

1. Knight *et al.* 2010. Gut 59 (suppl III); A288 (P0899).
2. Moselinger *et al.* 2006. Life Sci 79, 374.